A 2023 follow-up found that the combination improved mitochondrial function, reduced oxidative stress biomarkers, and reversed multiple hallmarks of biological ageing effects that neither supplement produced in isolation.[4] The magnet works as designed
Unlike anti-inflammatory drugs that can impair healing by suppressing necessary processes, the combination modulates inflammation appropriately reducing the excess that causes tissue damage while preserving whats needed for debris clearance and the start of healing

Hypothetical Dosing Considerations While no evidence-based cagrilintide dosage with retatrutide protocol exists, theoretical frameworks based on monotherapy data suggest several principles that would likely apply: Conservative Approach Principles: Start with minimal doses Perhaps 0.3 mg cagrilintide + 2 mg retatrutide weekly Extended titration periods 16-24 weeks to reach target doses instead of standard 8-12 weeks Alternating escalation Increase one compound while holding the other stable Frequent monitoring Weekly check-ins during initial phases Lower maximum doses Perhaps 1.2 mg cagrilintide + 8 mg retatrutide rather than maximum monotherapy doses These suggestions remain purely speculative and should not be interpreted as clinical recommendations
All resolved without intervention
For example, topical application of GHK-Cu (a copper-bound form of GHK) has been clinically investigated for enhancing skin repair, reducing inflammation, and promoting angiogenesis